ClinicalTrials.gov
public full text
Public Domain
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies#148759
- A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)#1210910
- BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma#1281217
- Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies#1111517
- A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors#918144
Record · ID 1259610
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive